News

Federated Hermes to Expand with Acquisition of FCP Fund Manager

Federated Hermes to Expand with Acquisition of FCP Fund Manager

Federated Hermes Acquires Majority Interest in FCP Fund Manager

Federated Hermes, Inc. (NYSE: FHI), a leader in active investment management with a substantial asset base, has announced its agreement to acquire an 80% stake in FCP Fund Manager, L.P. This acquisition marks a significant milestone in Federated Hermes' ongoing effort to enhance its presence in private markets and alternatives investment strategies.

Strengthening Private Markets Investment Strategies

This acquisition reinforces Federated Hermes' commitment to expanding its capabilities within private markets and alternatives, reflecting an assertive strategic direction as it navigates an evolving investment landscape. The move aligns with its overarching objective of enhancing investment solutions for clients seeking diversification and growth.

Expansion into Major U.S. Markets

Federated Hermes' acquisition is set to expand its real estate investment capabilities into major U.S. markets, complementing its established operations in the U.K. This strategic posture not only enhances the company’s operational footprint but also broadens its expertise in real estate, significantly enhancing its competitiveness.

Institutional Strength and Local Expertise

FCP brings significant institutional strength to this partnership, having invested over $14.6 billion in gross asset value since its inception. The firm’s remarkable track record includes the operation and financing of more than 75,000 multifamily apartment units, bolstering Federated Hermes' ambition to excel in the real estate sector.

Details of the Acquisition

The purchase agreement specifies an aggregate consideration of up to $331 million, which comprises $215.8 million in cash and $23.2 million in Federated Hermes Class B common stock, payable at the closing. The transaction further stipulates the possibility of contingent consideration amounting to $92 million over subsequent years, contingent on performance metrics post-acquisition.

Reinforcing Real Estate Operations

This transaction will allow Federated Hermes to harness FCP’s extensive local knowledge and market expertise in 19 priority U.S. markets. As a result, Federated Hermes can offer refined real estate investment solutions tailored to meet the needs of its clientele amidst a growing demand for multifamily housing.

Leadership Statements on Strategic Fit

J. Christopher Donahue, president and CEO of Federated Hermes, expressed enthusiasm about the acquisition, stating it enhances the firm’s position in the U.S. real estate market at a time characterized by robust fundamentals and growth opportunities in the multifamily sector. He underscored FCP's impressive long-term investment performance and deep-rooted relationships as pivotal for future success.

Future Prospects and Growth Expectations

With this strategic acquisition, Federated Hermes anticipates substantial growth and the ability to meet increasing client needs for innovative real estate investment products. The firm aims to not only bolster its U.S. operations but also to align them closely with its existing U.K. real estate functions, which have a legacy dating back to 1983.

FCP’s Vision and Alignment

Esko Korhonen, FCP's founding managing partner, remarked on the alignment of values and mission with Federated Hermes, emphasizing the shared commitment to enhancing their private markets operations. This partnership is seen as a pathway for FCP to further solidify its position within the U.S. real estate landscape, underpinned by enhanced resources and collaboration.

Consulting and Advisory Support

Throughout this transaction, Federated Hermes received legal representation from K&L Gates LLP, while consultancy support was provided by KPMG LLP and Hodes Weill & Associates. FCP was advised by Goodwin Procter LLP and Berkshire Global Advisors, showcasing the collaborative effort behind this strategic acquisition.

Conclusion and Next Steps

The transaction has received approval from the board of directors of both Federated Hermes and FCP, with expectations to close in the first half of 2026, pending certain regulatory approvals. This partnership marks Federated Hermes’ second acquisition in the private markets this year, following its acquisition of Rivington Energy Management Limited earlier in the year, demonstrating a clear trajectory toward growth and innovation.

Frequently Asked Questions

What is the significance of Federated Hermes acquiring FCP Fund Manager?

This acquisition allows Federated Hermes to strengthen its real estate investment capabilities and expand into significant U.S. markets.

What are the financial terms of the acquisition?

The agreement includes up to $331 million in total consideration, comprising cash and Federated Hermes stock.

How does this acquisition impact future growth?

It positions Federated Hermes for enhanced growth by leveraging FCP’s local expertise and established track record in real estate.

Who were the advisors involved in this acquisition?

Federated Hermes was advised by K&L Gates LLP and KPMG LLP, while FCP had Goodwin Procter LLP and Berkshire Global Advisors.

When is the expected closing date for the transaction?

The acquisition is anticipated to close in the first half of 2026, subject to regulatory approvals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

NanoXplore Gains Government Support for Innovative Battery Tech

Updated Category News Views 193

NanoXplore Secures Government Funding for Battery Innovation In a significant development for the battery technology sector, NanoXplore Inc. (TSX: GRA and OTCQX: NNXPF), a frontrunner in graphene production, recently announced a contribution of up to $2.75 million from the Canadian government as part of the Energy Innovation Program (EIP). This contribution is expected to...

Continue Reading
Equinor ASA Declares Cash Dividend for First Quarter 2025

Updated Category News Views 272

Equinor ASA Announces an Exciting Cash Dividend Equinor ASA (OSE: EQNR, NYSE: EQNR) has made an important announcement regarding its dividend strategy for shareholders. As part of its ongoing commitment to deliver value, the company has declared a cash dividend of NOK 3.7740 per share for the first quarter of 2025. Understanding the Dividend Amount The cash dividend of...

Continue Reading
RIAS A/S Shares Insights from Recent Half-Year Performance

Updated Category News Views 469

Analyzing the Half-Year Performance of RIAS A/S RIAS A/S has recently released its half-year report, offering a clear view into the company's operational status and financial health. This report is crucial for stakeholders and potential investors to understand how RIAS A/S is navigating through the current economic landscape. Key Financial Highlights In this reporting...

Continue Reading
Starbucks Stock Analysis: Opportunities and Challenges Ahead

Updated Category News Views 156

Understanding Starbucks Stock Performance Starbucks Corporation's stock, trading under the ticker SBUX, is currently observed at a forward 12-month Price/Earnings ratio of 24.79x. This figure places it just slightly below the Zacks Restaurant industry average of 24.97x. However, it's noteworthy that SBUX's valuation exceeds the broader Retail-Wholesale sector, which has a...

Continue Reading
Explore Innovations at the 2024 GenScript Biotech Forum

Updated Category News Views 314

Join Experts at the 2024 GenScript Biotech Global Forum The year ahead is shaping up to be crucial for Cell and Gene Therapy (CGT), and the "2024 GenScript Biotech Global Forum" offers an ideal setting for essential discussions. Top experts will gather to exchange insights on groundbreaking therapies such as Amtagvi and PM359, which promise new opportunities in treatment....

Continue Reading